Budesonide (targeted-release) · TARPEYO / Nefecon

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: IgA Nephropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
Product first approved 2021FDA label
CN
  • Primary immunoglobulin A nephropathy (NEFECON, full approval of the sNDA)
Product first approved 2025acnnewswire.com
EU
  • Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
IgA Nephropathy
NCT05534919 · Everest Medicines (Singapore) Pte. Ltd.
2022-12-09 – 2024-07-17 · Primary Immunoglobulin a Nephropathy (IgAN)
What this study did
NCT04541043 · Calliditas Therapeutics AB
2020-11-17 – 2024-02-26 · Primary IgA Nephropathy
What this study did
Phase 2 (1)
IgA Nephropathy
NCT01738035 · Calliditas Therapeutics AB
2012-12 – 2015-09 · Primary IgA Nephropathy
What this study did
Phase 4 (5)
IgA Nephropathy
NCT06676384 · Christian Medical College, Vellore, India
2025-02-15 – 2029-08 · IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
What this study did
NCT06528015 · Gang Xu
2024-07 – 2028-12-31 · Glomerulonephritis, IGA, Probiotics, Budesonide
What this study did
NCT07604311 · Nanfang Hospital, Southern Medical University
2026-06-23 – 2028-12-31 · IgA Nephropathy (IgAN)
What this study did
NCT06712407 · Calliditas Therapeutics AB
2024-12-17 – 2028-02 · IgA Nephropathy
What this study did
NCT07030894 · The First Hospital of Jilin University
2025-09-01 – 2026-12-31 · IgA Nephropathy, Chronic Kidney Disease, Proteinuria
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
IgA Nephropathy
NCT06922305 · Jiangsu HengRui Medicine Co., Ltd.
2023-12-27 – 2024-01-25 · Primary IgA Nephropathy; Autoimmune Hepatitis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for IgA Nephropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Budesonide (targeted-Release) (TARPEYO / Nefecon): this drugApprovedSmall moleculeGlucocorticoid receptorReliable signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)
Approved(overall)
CombinationBeta-2 adrenergic receptor, Glucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
AtaciceptApprovedProtein / enzyme therapeuticBLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Partial signalFeatured results are non-efficacy only in this race
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptorPartial signal
NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001
Beclomethasone (QVAR)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Entocort EC)
Approved(overall)
Small moleculeGlucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Ortikos)
ApprovedUS marketing discontinued (overall)
—Glucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide MMX (Uceris)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Ciclesonide (Alvesco)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Dexamethasone
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate (Arnuity Ellipta)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Vilanterol (Breo Ellipta)
Approved(overall)
Small moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair HFA)
Approved(overall)
CombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing.
Relacorilant (Lifyorli)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Sparsentan (Filspari)ApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalFeatured results are non-efficacy only in this race
Lodotra (Rayos)
US approval withdrawn(overall)
—Glucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
JADE101Phase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
SefaxersenPhase 3RNA / oligonucleotideComplement factor B (CFB)Partial signal
NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
Dazucorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ARO-CFBPhase 1RNA / oligonucleotideComplement factor B (CFB) mRNAnot yet gradedNo reviewed efficacy summary in this indication
Opemalirsen
Phase 1(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TARPEYO / Nefecon (Budesonide (targeted-release)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4IgA NephropathyNot yet recruiting
Est. primary completion 2026-12-31 · NCT06528015 · CT.gov ↗
What to watch
Phase 4IgA NephropathyRecruiting
Est. primary completion 2026-12-31 · NCT07030894 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Phase 4IgA NephropathyActive not recruiting
Est. primary completion 2027-03 · NCT06712407 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 4IgA NephropathyRecruiting
Est. primary completion 2028-12-01 · NCT07604311 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 4IgA NephropathyRecruiting
Est. primary completion 2029-08 · NCT06676384 · CT.gov ↗
What to watch

See the full readout calendar ↗